The European Innovation Shift is reshaping how senior leaders in health economics and market access approach evidence generation, regulatory timing and national uptake. As development activity moves away from Europe, the data available for value assessment changes in both quantity and relevance, carrying direct consequences for pricing strategies, reimbursement decisions and long-term system sustainability.

Strategic context for decision-makers

Over the past two decades Europe has seen its share of global pharmaceutical R&D decline even while absolute spending rose. Commercial clinical trial activity within the EEA has halved as a proportion of the world total, and the region now accounts for a smaller share of first regulatory approvals. These trends alter the sequence in which comparative data and real-world evidence reach European health technology assessment bodies and payers.

Implications for health economics and value assessment

Health economics teams must now work with evidence packages that are more likely to be generated outside European populations. This increases uncertainty in cost-effectiveness models and raises the chance that budget impact projections will require adjustment once local utilisation data emerge. Value-based pricing discussions become more complex when the initial patient experience sits elsewhere, because generalisability assumptions weaken and payers demand additional local evidence before committing to broad reimbursement.

Consequences for pricing strategies and reimbursement decisions

The revised General Pharmaceutical Legislation ties certain extensions of market protection to EU-centred development and high-quality comparative evidence. Companies that maintain sequential rather than parallel filing therefore risk losing incremental protection periods. At the same time, the widened Bolar exemption accelerates the entry of follow-on products into national appraisal processes, shortening the window during which premium prices can be sustained. Payers will need to model faster generic or biosimilar competition when calculating budget impact over a product’s lifecycle.

System dynamics and policy implications

Reduced early-phase trial activity means fewer European patients receive pre-licence access to investigational therapies, shifting more of the cost of early adoption onto formal reimbursement systems. For advanced therapies, manufacturing capacity and specialist centres are path-dependent; once development moves, rebuilding capability takes years. Joint Clinical Assessment under the HTA Regulation can shorten timelines only if the evidence submitted meets European standards; otherwise national bodies still face duplication and delay. Policy implications extend beyond medicines law to the European Health Data Space and rules governing AI in discovery, because these enablers determine whether Europe can regain ground in evidence generation.

Recommendations for HEOR, market access and HTA bodies

Companies should align EU evidence generation and filing timing with global development plans from the outset so that near-simultaneous submission qualifies for available incentive extensions. The European Innovation Shift rewards those who treat research location, regulatory timing and uptake speed as connected variables. Payers and HTA bodies should favour outcome-based or coverage-with-evidence-development schemes that convert evidence gaps into structured data collection rather than prolonged negotiation. National authorities that have improved trial start-up times should share operational lessons, because administrative speed directly influences location decisions. At European level, implementation of the pharmaceutical legislation, the Biotech Act and data-sharing frameworks must be judged against a single criterion: whether they shorten the interval between authorisation and predictable, evidence-informed reimbursement.

Conclusion

The European Innovation Shift matters well beyond industrial policy. It changes the evidence base for health economics, the room for value-based pricing, and the budget impact of new therapies. Decision-makers who treat research location, regulatory timing and uptake speed as connected variables will be better placed to secure sustainable access and continued investment in European biomedical capability.

Frequently Asked Questions

How does the European Innovation Shift affect drug pricing in Europe?

It complicates value-based pricing by increasing reliance on non-European data, which often leads payers to request extra local evidence and shortens the period for maintaining premium prices due to faster generic competition.

What should companies do to respond to the European Innovation Shift?

Align EU evidence generation and filing timing with global plans early, pursue simultaneous submissions where possible, and engage in outcome-based agreements that build real-world data while securing reimbursement.

Will the European Innovation Shift reduce patient access to new therapies?

It can delay access if evidence gaps persist, but coordinated policy action on trial start-up times, data sharing and joint assessments can help restore timely, evidence-informed uptake across member states.